Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Cost of Revenue (2024 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Cost of Revenue for 2 consecutive years, with $351000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue rose 54.63% year-over-year to $351000.0, compared with a TTM value of $5.7 million through Sep 2025, up 1050.51%, and an annual FY2024 reading of $797000.0, changed N/A over the prior year.
  • Cost of Revenue was $351000.0 for Q3 2025 at X4 Pharmaceuticals, up from $326000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $4.7 million in Q1 2025 and bottomed at $227000.0 in Q3 2024.